Business Context and Reporting Period
This Form 8-K reports on the 2023 Annual Meeting of Stockholders held by AnaptysBio, Inc. on June 15, 2023. The company is incorporated in Delaware and its common stock trades on The Nasdaq Stock Market under the symbol "ANAB."
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate governance matters and voting results.
Material Changes and Voting Results
Four proposals were submitted to and adopted by the stockholders:
- Election of Directors: Three Class III directors were elected to three-year terms: Magda Marquet, Ph.D., Hollings Renton, M.B.A., and John P. Schmid.
- Auditor Ratification: KPMG LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2023.
- Executive Compensation: A non-binding, advisory vote approved the compensation paid to named executive officers.
- Corporate Governance: Stockholders approved an amendment to the Certificate of Incorporation permitting the exculpation of officers.
Guidance, Outlook, and Risks
The filing does not provide management commentary, financial guidance, outlook, or specific risk factors. It is a procedural report regarding the outcome of the annual meeting.
Investor Verification Checklist
- Verify the tenure and background of the newly elected directors (Marquet, Renton, Schmid).
- Review the specific terms of the Certificate of Incorporation amendment regarding officer exculpation.
- Examine the "Say-on-Pay" vote results, noting that approximately 32% of votes cast were against the executive compensation proposal.
- Confirm the appointment of KPMG LLP as the auditor for the 2023 fiscal year.